Skip to main content
. 2016 Mar 22;127(22):2742–2750. doi: 10.1182/blood-2016-01-690230

Table 2.

Treatment response based on the emergence phase of ACAs

Phase Group 1 Group 2
Trisomy 8 −Y Extra Ph i(17)(q10) −7/del(7q) 3q26
CP
 CCyR 12/21 (57%) 17/26 (65%) 11/16 (69%) 2/9 (22%) 1/3 (33%) 0/11 (0%)
 MMR 11/21 (52%) 16/26 (62%) 9/16 (56%) 1/9 (11%) 0/3 (0%) 0/11 (0%)
AP + BP
 CCyR 0/1 (0%) N/A 1/3 (33%) 0/6 (0%) 0/1 (0%) 0/8 (0%)
 MMR 0/1 (0%) N/A 1/3 (33%) 0/6 (0%) 0/1 (0%) 0/8 (0%)

N/A, not available.